Guiding immunotherapy based on the oxford classification activity score in IgA nephropathy
-
By
-
Jingjing Nong
-
Yuhong Tang
-
Jiazhen Yang
-
Wenli Wei
-
Licong Su
-
Sheng Nie
-
Jun Ou
-
June 23, 2026
-
Clinical Scorecard: Utilizing Oxford Classification Activity Scores to Direct Immunotherapy in IgA Nephropathy
At a Glance
| Category | Detail |
|---|
| Condition | IgA Nephropathy |
| Key Mechanisms | Oxford classification scores (M, E, C) and their association with immunotherapy responsiveness. |
| Target Population | Patients diagnosed with IgA nephropathy, particularly those with high SumMEC scores. |
| Care Setting | Clinical management of IgA nephropathy with a focus on immunotherapy. |
Key Highlights
- Immunotherapy associated with a 22% increase in proteinuria remission at 12 months.
- High SumMEC scores correlate with positive immunotherapy response.
- Oxford classification serves as a prognostic tool but is debated for treatment guidance.
Guideline-Based Recommendations
Diagnosis
- IgA nephropathy confirmed by renal biopsy.
Management
- Immunotherapy may improve proteinuria remission in patients with high SumMEC scores.
Monitoring & Follow-up
- Monitor proteinuria levels as a biomarker for treatment response.
Risks
- Potential lack of benefit from immunotherapy in patients with specific histopathological features.
Patient & Prescribing Data
2,389 patients diagnosed with IgA nephropathy.
Immunosuppressive therapy may be beneficial for patients with high SumMEC scores.
Clinical Best Practices
- Utilize Oxford classification scores to assess disease activity.
- Consider composite scores like SumMEC for treatment decisions.
Related Resources & Content
